Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with... | March 29, 2023

Related Keywords

South Korea ,Bobt Li ,Boltbody Isacs ,Editha Perez ,Biotherapeutic Boltbody ,Karenl Bergman ,David Melamed ,Sarah Mccabe ,Memorial Sloan Kettering Cancer Center ,Clinical Program ,Russo Partners ,Bristol Myers Squibb ,Bolt Biotherapeutics Inc ,Nasdaq ,Stern Investor Relations Inc ,Exchange Commission ,Immune Stimulating Antibody Conjugate ,Chief Medical Officer ,Roche Supporting Phase ,Myers Squibb ,Boltbody Immune Stimulating Antibody Conjugate ,Annual Report ,Media Contacts ,Investor Relations ,Bolt Biotherapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Unsolicited ,Objective ,Linical ,Ncluding ,Multiple ,Mrs ,End ,Table ,Cross ,Diverse ,Pet ,F ,Olid ,Humor ,Types ,N ,Monotherapy ,Ombination Bolt Us0977021049 ,